... announced the publication of a patent application in Japan covering novel compositions and methods for treating dyskinesia, a neurological movement disorder characterized by involuntary movements.
reduction or loss of active muscle movement. A research team is investigating this approach based on the work carried out on babies with spinal muscular atrophy (SMA), a rare genetic neuromuscular disorder.